[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,716,208
  • Shares Outstanding, K 305,375
  • Annual Sales, $ 75,130 K
  • Annual Income, $ -146,410 K
  • EBIT $ -188 M
  • EBITDA $ -159 M
  • 60-Month Beta 1.18
  • Price/Sales 25.89
  • Price/Cash Flow N/A
  • Price/Book 2.07

Options Overview Details

View History
  • Implied Volatility 110.66% (+6.06%)
  • Historical Volatility 102.14%
  • IV Percentile 71%
  • IV Rank 13.85%
  • IV High 335.35% on 02/04/26
  • IV Low 74.55% on 12/24/25
  • Expected Move (DTE 12) 1.02 (18.15%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 4,425
  • Volume Avg (30-Day) 10,732
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 149,883
  • Open Int (30-Day) 105,238
  • Expected Range 4.60 to 6.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 2
  • High Estimate $-0.16
  • Low Estimate $-0.17
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.94 +42.64%
on 05/19/26
6.79 -17.23%
on 06/01/26
+0.96 (+20.60%)
since 05/05/26
3-Month
3.22 +74.53%
on 04/07/26
6.79 -17.23%
on 06/01/26
+2.03 (+56.55%)
since 03/05/26
52-Week
2.38 +136.13%
on 06/06/25
6.79 -17.23%
on 06/01/26
+3.25 (+137.13%)
since 06/05/25

Most Recent Stories

More News
AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. “Dr. Sandor is an experienced director...

ABCL : 5.62 (-11.77%)
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during...

ABCL : 5.62 (-11.77%)
AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation...

ABCL : 5.62 (-11.77%)
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. ...

ABCL : 5.62 (-11.77%)
AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...

ABCL : 5.62 (-11.77%)
AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...

ABCL : 5.62 (-11.77%)
AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...

ABCL : 5.62 (-11.77%)
AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026...

ABCL : 5.62 (-11.77%)
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic...

ABCL : 5.62 (-11.77%)
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...

ABCL : 5.62 (-11.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 6.96
2nd Resistance Point 6.65
1st Resistance Point 6.13
Last Price 5.62
1st Support Level 5.30
2nd Support Level 4.99
3rd Support Level 4.47

See More

52-Week High 6.79
Last Price 5.62
Fibonacci 61.8% 5.11
Fibonacci 50% 4.59
Fibonacci 38.2% 4.06
52-Week Low 2.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.